Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Cytokinetics Inc
CYTKCurrent price
54.09 USD
-2.1 USD (-3.74%)
Last closed
55.93 USD
Company
www.cytokinetics.com
ISIN
US23282W6057
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
6 716 033 024 USD
Yield for 12 month
+50.00 %
1Y
3Y
5Y
10Y
15Y
CYTK
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California. Address: 350 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
80.65 USDP/E ratio
–Dividend Yield
–Current Year
+7 530 000 USD
Last Year
+94 588 000 USD
Current Quarter
+249 000 USD
Last Quarter
+835 000 USD
Current Year
-4 362 000 USD
Last Year
-146 225 000 USD
Current Quarter
-2 157 000 USD
Last Quarter
-1 496 000 USD
Key Figures CYTK
1 year
3 years
5 years
10 years
EBITDA
-493 164 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-27.46 %
PEG Ratio
-0.42
Return On Equity TTM
-572.15 %
Wall Street Target Price
80.65 USD
Revenue TTM
3 134 000 USD
Book Value
0.92 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-71.3 %
Dividend Yield
–
Gross Profit TTM
-146 225 000 USD
Earnings per share
-5.36 USD
Diluted Eps TTM
-5.36 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics CYTK
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History CYTK
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1:6
Payout Ratio
–
Last Split Date
25.06.2013
Dividend Date
–
Stock Valuation CYTK
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
2056.0073
Price Sales TTM
2142.9587
Enterprise Value EBITDA
-15.824
Price Book MRQ
61.816
Financials CYTK
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators CYTK
For 52 weeks
25.98 USD
110.25 USD
50 Day MA
56.01 USD
Shares Short Prior Month
17 832 699
200 Day MA
61.33 USD
Short Ratio
14.21
Shares Short
18 634 439
Short Percent
24.2 %
BeatStart